A Research Guide for
Charcot-Marie-Tooth

Diagnosis

CMT is diagnosed by recognizing its characteristic pattern, supported by nerve tests and confirmed by genetic testing. Getting a clear diagnosis — and ideally the specific type — guides care and family planning.

CMT in children

When CMT begins in childhood (as the common CMT1A type often does), the early signs can be subtle and easy to misread: a child who is clumsy, trips often, is “not sporty,” has trouble keeping up running, develops high-arched feet or curled toes, or wears out shoes unevenly. Some children have delayed motor milestones; others seem fine until later. Recognizing CMT in a child is valuable because it allows early support — physical therapy, the right footwear and braces, and monitoring of the feet and spine — that helps the child stay active and comfortable, and it informs the family. Importantly, children with CMT can and should stay physically active; sensible activity is good for them, and a physical therapist can suggest suitable sports and exercises. School staff may need to understand that fatigue and difficulty with certain physical tasks are real, not a lack of effort. If a child has these signs — especially with a family history of similar foot or walking problems — it's reasonable to ask about CMT and seek evaluation by a pediatric neurologist. Early, supportive care sets children up to do well.

Recognizing CMT

Common clues include slowly progressive weakness and changes starting in the feet (high arches, hammertoes, foot drop, frequent ankle sprains or tripping), thinning of the lower-leg muscles (sometimes described as “stork legs” or an “inverted champagne bottle” shape), reduced sensation in the feet, balance difficulties, and later weakness or clumsiness of the hands. Reduced or absent reflexes are common. A family history of similar foot problems or “weak ankles” is an important clue, though some people are the first in their family to be affected.

The family-history clue

Family history is one of the most useful pieces of the puzzle in CMT, because the condition is inherited — but it can be easy to miss. Relatives with CMT may never have been formally diagnosed, instead being known for “weak ankles,” “bad feet,” high arches, frequent ankle sprains, or a particular way of walking; an older relative's foot surgery or difficulty with stairs may, in hindsight, have been CMT. So when CMT is suspected, it's worth gently asking about these patterns across the family. That said, not everyone with CMT has a known family history: some people are the first in their family to be affected (a new gene change), and in the X-linked form, female relatives may have only mild or no symptoms while still carrying and passing on the gene. Bringing any family information you have to your appointment — and being open to the possibility even without a clear family history — helps your doctor recognize CMT and decide which genetic tests make sense. Once a diagnosis is made, it can also be valuable (and sometimes a relief) for relatives to understand their own situation.

The tests

• Clinical examination — assessing the pattern of weakness, sensation, reflexes, and foot shape.
• Nerve conduction studies / EMG — tests that measure how well the nerves carry signals, helping confirm a neuropathy and distinguish demyelinating (CMT1) from axonal (CMT2) types.
• Genetic testing — the definitive test, identifying the specific gene change (such as the PMP22 duplication of CMT1A). It confirms the diagnosis, identifies the type, and enables accurate family counseling.

Treatable conditions that can mimic CMT

One important reason to get a clear, confirmed diagnosis is that a few other nerve conditions can resemble CMT — and some of those are treatable, so it matters not to assume every slowly progressive neuropathy is CMT. Two examples stand out. CIDP (an inflammatory nerve condition) can look like the demyelinating form of CMT but responds to immune treatments; clues that point to CIDP rather than CMT include a faster or more uneven course or particular nerve-test findings. Hereditary ATTR amyloidosis is an inherited condition that can slowly mimic the axonal type of CMT, and — importantly — it now has effective approved treatments (such as tafamidis, patisiran, vutrisiran, and eplontersen), so recognizing it changes everything. Because these treatable look-alikes can be subtle, this is another reason that genetic testing and evaluation by a neuromuscular specialist are worthwhile, especially if there's no clear family history of CMT, if the course is unusual, or if there are features (like heart or autonomic symptoms) that aren't typical of CMT. Getting the precise diagnosis ensures you receive treatment for a treatable condition if that's what you have.

Questions to ask your doctor

• Has my diagnosis been confirmed, and is my specific type known?
• Would genetic testing add useful information for me or my family?
• What does my type suggest about the likely course?
• Who should coordinate my ongoing care?

Treatment & Management

There is no medicine yet that cures or slows CMT, but — importantly — that does not mean nothing can be done. A great deal of effective, practical care maintains function, comfort, mobility, and independence, and protecting the nerves from harm is a key part of the plan.

Why supportive care is so effective

It's easy to hear “there's no cure” and feel that little can be done — but the opposite is true, and understanding why helps you make the most of care. In CMT, much of the day-to-day difficulty comes not only from the nerve changes themselves but from their downstream effects: foot drop that causes tripping, foot deformities that make walking painful or shoes uncomfortable, weakened balance that risks falls, and the deconditioning that creeps in when activity drops. These downstream effects are exactly what supportive care targets — and they respond well. A good ankle-foot brace can transform an unstable, tiring gait into a confident one; physical therapy maintains the strength and balance you have and slows the deconditioning spiral; foot care and the right footwear prevent painful wounds and deformity progression; and treating pain keeps you active. None of this changes the underlying genetics, but all of it changes how well you function and feel day to day — which is what quality of life is built from. So while research works toward disease-changing medicines, the supportive tools available right now genuinely and measurably improve life with CMT. They are worth pursuing fully, not as a fallback, but as the core of effective care today.

Therapy, exercise, and devices

Physical therapy helps maintain strength, flexibility, and balance, and reduces the risk of falls; occupational therapy helps with hand function and daily tasks. Moderate exercise — such as walking, swimming, or cycling, plus balance work — is encouraged and beneficial (the aim is to stay fit and maintain function, not to exhaust muscles). Ankle-foot orthoses (AFOs) — braces that support the foot and ankle — are one of the most valuable tools for foot drop, improving walking and stability; other devices, special footwear, and orthotics help too. As needs change, mobility aids and home adaptations support independence.

A little more on braces, because they are so central. Ankle-foot orthoses (AFOs) come in different styles — from lightweight, flexible carbon-fiber designs to more supportive rigid ones — and a good orthotist matches the brace to your needs, helping with foot drop, stability, and walking efficiency, often dramatically. Many people are initially reluctant to use braces, seeing them as a sign of decline, but most who try well-fitted AFOs find they walk more confidently, trip less, and tire less — in other words, braces enable activity rather than limit it. It can take a little time to get the fit and style right, so it's worth persisting and giving feedback to your orthotist. Beyond AFOs, supportive footwear, custom insoles for high-arched feet, and sometimes other devices (canes, walking poles) all help. As your needs change over the years, your braces and aids can be updated. Pairing the right orthotics with ongoing physical therapy is one of the most effective things you can do to stay mobile.

Foot care and surgery

Because CMT affects the feet so commonly — high arches, hammertoes, and reduced sensation — good foot care matters: well-fitting protective footwear, daily checks for sores or injuries (which may not be felt), and prompt attention to any wounds. When foot deformities cause significant pain or difficulty walking despite braces and orthotics, orthopedic foot surgery can sometimes correct the alignment and improve function; this is considered individually with an orthopedic specialist familiar with CMT.

On foot surgery specifically: it is not needed by everyone, and braces and orthotics are always tried first — but for some people, the foot deformities of CMT (a fixed high arch, clawed toes, an ankle that rolls) become painful or make walking and bracing difficult, and surgery can genuinely help. Operations range from soft-tissue procedures (releasing or rebalancing tendons) to bone procedures that realign the foot, sometimes combined. The goals are a more stable, better-aligned, pain-free foot that fits comfortably in shoes and braces. Timing and the choice of procedure matter and should be planned with an orthopedic surgeon experienced in CMT, because the underlying muscle imbalance needs to be taken into account so the correction lasts. Recovery takes time and rehabilitation, but for well-selected people the improvement in comfort and walking can be substantial. If foot problems are limiting you despite good braces and footwear, it's reasonable to ask for a referral to discuss whether surgery could help. Ask: "My feet are painful even with braces — could surgery help, and should I see an orthopedic surgeon who is experienced with CMT?" And on timing: "Is now the right time, or should we wait, given how CMT changes the muscle balance in the foot?"

Pain and other symptoms

Many people with CMT experience pain — musculoskeletal pain from altered mechanics and posture, and sometimes neuropathic (nerve) pain — and it is very treatable with a combination of therapy, footwear/braces, and medicines where appropriate. Muscle cramps, fatigue, and cold-sensitive hands and feet are common and can be managed. The key message is that symptoms should not simply be endured — tell your team, because most can be eased.

Because pain is common and sometimes under-discussed in CMT, it is worth a closer look. Two kinds tend to occur. Musculoskeletal pain — in the feet, ankles, knees, hips, and back — arises from the altered shape and mechanics of the feet and from changes in how you walk and stand; it often responds well to the right braces and footwear, physical therapy, posture and gait work, and sometimes standard pain relievers. Neuropathic pain — burning, tingling, or shooting sensations from the affected nerves — is less universal but, when present, can be treated with medicines specifically for nerve pain. Muscle cramps, especially at night, are also common and can be eased with stretching, hydration, and sometimes medication. The important message is that you should not simply put up with pain: tell your care team, because a tailored combination of physical measures and, where needed, medicine usually brings meaningful relief. Managing pain well also helps you stay active, which in turn helps maintain function — so it's worth addressing rather than enduring.

When medicine is used for nerve (neuropathic) pain, doctors usually start at a low dose and build up slowly, giving each medicine a fair trial period before judging whether it helps. None of these is a treatment for CMT itself; they are labeled by the FDA for other nerve-pain conditions and used here only to ease symptoms. Common ones, with reference doses taken from the manufacturers’ FDA labels, include gabapentin (FDA label for post-shingles nerve pain: 300 mg on day 1, then built up over several days to about 1,800 mg a day in three divided doses), pregabalin (FDA label for diabetic nerve pain: 150 mg a day to start, increased to a maximum of 300 mg a day), and duloxetine (FDA label for diabetic nerve pain: 60 mg once a day). Your doctor selects and doses these individually; the numbers here are reference doses from the labels, not a recommendation. A nerve-pain medicine is generally discontinued if it gives no meaningful relief after an adequate trial at the target dose, and pregabalin and duloxetine should be tapered rather than stopped abruptly (the pregabalin FDA label advises reducing the dose over at least one week).

The medicines to avoid or use with caution — in detail

This is one of the most important and practical parts of living safely with CMT, so it is worth understanding, not just filing away. Because your peripheral nerves are already vulnerable, certain drugs that are only mildly nerve-toxic for other people can cause serious, sometimes lasting harm in CMT. The list below is drawn from the Charcot-Marie-Tooth Association (CMTA) medication-safety guidance and the published case-report literature; it is grouped by how strong the concern is. None of this means you can never receive medical care — it means the choice should be made knowingly, with your CMT flagged, and safer alternatives used when they exist.

• Vincristine — effectively off-limits (the single most important one). This chemotherapy drug can cause rapid, severe, and sometimes permanent worsening of CMT — even paralysis — after as little as one or two doses, and it has done so even in people whose CMT was mild or not yet diagnosed. The CMTA lists it in its highest-risk category, and it is generally considered contraindicated in CMT (especially CMT1A). If you are ever told you need vincristine (it is used for some lymphomas and leukemias), this is an emergency-level conversation: your oncologist and a neurologist should discuss it together, because alternatives usually exist.
• Other chemotherapy nerve-toxins — high caution. The taxanes (paclitaxel/Taxol, docetaxel/Taxotere), the platinum drugs (cisplatin, oxaliplatin), thalidomide and lenalidomide, bortezomib, and suramin all carry a meaningful risk of worsening neuropathy. If cancer treatment is needed, it can often still go ahead — but the CMT must be on the table so the oncology team can weigh alternatives, adjust doses, and monitor closely.
• Common non-cancer drugs to use cautiously. These are prescribed far more often, so they matter day to day: nitrofurantoin (a frequent urinary-tract-infection antibiotic — ask for an alternative such as trimethoprim or fosfomycin), metronidazole (Flagyl — a concern mainly with prolonged or high-dose courses), amiodarone (a heart-rhythm drug), leflunomide (used in rheumatoid arthritis), dapsone, and long-term high-dose pyridoxine (vitamin B6), which is itself nerve-toxic in large amounts. Many others appear on the CMTA "use with caution" list.
• A note on isoniazid (a TB antibiotic). It can cause neuropathy, but this is largely preventable by taking vitamin B6 (pyridoxine) alongside it at the standard preventive dose — a good example of why the conversation, not blanket avoidance, is the goal.

The reason this list is so powerful is that acting on it costs nothing and prevents the worst outcomes in CMT. The single habit that protects you is making sure every clinician knows. Ask: "I have Charcot-Marie-Tooth disease — can you check this prescription against the CMT list of nerve-toxic drugs before I fill it?" And when you see a new doctor or dentist: "Please note in my chart that I have CMT and must not receive vincristine or other nerve-toxic medicines."

Medicines used for symptoms (not for CMT itself)

It bears repeating that no medicine currently treats CMT itself — the drugs below only ease symptoms such as nerve pain, and each is FDA-labeled for other nerve-pain conditions, then used here to help with symptoms. Doctors start low and increase slowly, and give each a fair trial period before judging it. Reference doses (from the manufacturers' FDA labels, on DailyMed) include:

• Gabapentin — 300 mg on day 1, then 300 mg twice on day 2 and 300 mg three times on day 3, built up over several days toward about 1,800 mg a day in three divided doses (studied up to 3,600 mg a day), lowered if the kidneys are impaired.
• Pregabalin — typically 75 mg twice a day (150 mg a day) to start, increased after about a week toward a maximum of 300 mg a day for diabetic nerve pain (up to 600 mg a day for post-shingles pain).
• Duloxetine — often 30 mg once daily for the first week, then 60 mg once daily; some people use 20 mg to ease in.
• Amitriptyline or nortriptyline (older tricyclic medicines, used off-label) at low bedtime doses such as 10 mg or 25 mg, occasionally up to 50 mg, weighing side effects.
• Tramadol (a weak opioid pain reliever, used sparingly and short-term) — commonly 50 mg to 100 mg every 4 to 6 hours as needed, not exceeding 400 mg a day per the label.
• Topical options for a localized area: a lidocaine 5% patch or capsaicin 8% patch/cream, which avoid whole-body side effects.

Two safety habits matter with all of these. First, the stop rule: a nerve-pain medicine is generally discontinued if it gives no meaningful relief after an adequate trial at the target dose, or if side effects outweigh benefit — there is no point staying on a drug that is not clearly helping. Second, do not stop gabapentin, pregabalin, or duloxetine abruptly — they should be tapered (the pregabalin FDA label advises reducing the dose over at least one week). And note that high-dose vitamin B6 (pyridoxine), sometimes taken as a supplement, is itself nerve-toxic above roughly 200 mg a day and should be avoided in CMT. Ask your neurologist: "If we try gabapentin or duloxetine, what dose are we aiming for, how long is a fair trial period, and when would we stop it if it isn't helping?" And: "Should I taper this rather than stop it suddenly?"

Questions to ask your doctor

• Would braces (AFOs), therapy, or other devices help me?
• How should I care for my feet and prevent falls?
• Is any of my pain treatable, and how?
• Which medicines must I avoid, and is this noted in my records?

Living Long-Term, Pregnancy & Trials

This section covers living with more advanced CMT, special situations, and the research bringing the first targeted treatments closer.

Living well as CMT progresses

CMT usually progresses slowly, and the focus over time is on maintaining mobility, independence, and quality of life. Priorities include keeping up with therapy and exercise to preserve strength and balance; updating braces and mobility aids as needs change; fall prevention (home safety, lighting, removing trip hazards); managing pain and fatigue; and protecting the hands (occupational therapy and adaptive tools help with buttons, writing, and fine tasks). Most people maintain good function with these supports; for the minority with more significant disability, a wider range of aids and home adaptations keeps daily life manageable. Fatigue is common and real — pacing and energy conservation help.

When CMT affects the hands

Although CMT usually starts in the feet, over time it can affect the hands — causing weakness of grip and of the small muscles, reduced fine-motor control, and sometimes reduced sensation — which can make tasks like buttoning, writing, opening jars, or using a keyboard harder. This is a common and understandable worry, but there is a lot that helps. Occupational therapy is key: a therapist can teach techniques and recommend simple adaptive tools (built-up grips, button hooks, jar openers, easier fasteners, voice-to-text for typing) that preserve independence in daily tasks and at work. Hand exercises and splints can help maintain function and comfort in some cases. Protecting the hands also matters — reduced sensation means being careful with heat and sharp objects. As with the feet, the message is that hand involvement is manageable with the right strategies and tools, and addressing it early — before it becomes limiting — preserves the most function. If you notice changes in your hands, raise it with your team so support can be put in place.

Understanding the course and outlook

People naturally want to know what to expect, and the honest answer is that CMT is highly variable — which argues against grim predictions and in favor of focusing on what you can do. In general, CMT progresses slowly over many years; most people remain walking and independent, using braces and aids as needed, and continue to work and pursue their lives. Some types (and some individuals) are milder, with little progression; others are more significant. Severity loosely relates to the type and to how early symptoms began, but these are not precise predictors for any one person, and even relatives with the same gene change can be affected quite differently. Importantly, CMT does not affect the brain or shorten life for the great majority, and the supportive treatments genuinely change the trajectory of function — braces, therapy, and foot care keep people mobile who might otherwise struggle. The most constructive approach is to stay active and engaged, keep up with therapy and the right equipment, protect your nerves from harmful drugs, and stay connected to expert care and the research community — because, with disease-targeted treatments now in trials, the outlook is genuinely improving.

Mobility aids and independence

As CMT progresses, mobility aids can be a positive tool rather than a setback — the goal is always to keep you doing what matters to you. Beyond ankle-foot braces, options that help at different stages include walking poles or a cane for balance and confidence, especially on uneven ground; a wheelchair or scooter for longer distances (which many people use selectively — for a day at a museum or airport — while walking normally otherwise, conserving energy for what they enjoy); and home and vehicle adaptations (handrails, ramps, hand controls) that maintain independence. Occupational therapists and physical therapists can recommend the right aids at the right time and ensure they fit your life. Many people find that using an aid increases what they can do — less fatigue, fewer falls, more confidence — rather than limiting them. There is no “giving in” in using a tool that helps; the measure of success is staying active, safe, and engaged in your life, by whatever means work best for you.

Pregnancy and family planning

CMT is inherited, so family planning is an important consideration. The chance of passing it on depends on the type: many forms are passed with a 50% chance to each child, while CMTX has a distinctive X-linked pattern (which affects the odds and severity differently for sons and daughters) — a genetic counselor can explain your specific situation and options, including prenatal testing and preimplantation genetic testing. During pregnancy, some women with CMT notice a temporary worsening of symptoms, and CMT can affect aspects of labor and delivery, so pregnancy is best managed by a team aware of the condition; most women with CMT have healthy pregnancies. As always, certain medicines (including some used around childbirth and anesthesia) warrant the usual CMT caution — ensure the team knows your diagnosis. Ask your obstetrician: "Because I have CMT, can my anesthesia and delivery plan be reviewed ahead of time, and can the team note my nerve-toxic-drug cautions?" Ask a genetic counselor: "What are the chances of passing my specific type to a child, and what testing options do we have?"

Clinical trials and research

For decades CMT had no disease-targeted treatment, and that is slowly beginning to change — but honesty matters here, because the road has had real setbacks alongside genuine progress. Here is where things actually stand as of July 2026 (trial numbers below are ClinicalTrials.gov identifiers you can look up directly).

PXT3003 for CMT1A — the most-studied candidate, with a mixed record

PXT3003 is a combination medicine (low doses of baclofen, naltrexone, and sorbitol) aimed at CMT1A. It has been through several trials: a phase 2 study (NCT01401257), a first phase 3 trial called PLEO-CMT (NCT02579759) and its long-term extension (NCT03023540), and a second confirmatory phase 3 trial called PREMIER (NCT04762758). In PLEO-CMT, the higher-dose arm suggested a benefit, but that trial was complicated by a formulation (stability) problem that forced the high-dose group to stop early. The follow-up PREMIER trial was designed to settle the question — and importantly, in early 2024 its sponsor reported that PREMIER did not meet its main goal: on the primary measure of disability, people on the drug and people on placebo both did about the same (and, unusually, both groups looked stable rather than declining). Some secondary measures favored the drug in certain subgroups, and a separate phase 3 trial run by a partner company (NCT05092841) has been completed, so the full picture is still being analyzed — but as of mid-2026, PXT3003 is not an approved treatment, and claims that it is "proven" would be premature. This is a realistic, not a discouraging, summary: it is exactly why supportive care and nerve protection remain the foundation today.

CMT-SORD — the subtype closest to a targeted medicine

The most encouraging near-term story is for the SORD form of CMT (CMT-SORD). An experimental drug, govorestat (also called AT-007), lowers the sorbitol that builds up in this subtype. In the phase 2/3 INSPIRE trial (NCT05397665), its maker reported that the study met key goals and that benefits held up through 24 months of treatment (results presented at the Peripheral Nerve Society meeting in 2025), and the company has been in discussions with the FDA about a possible approval path. It is not yet approved, and a planned confirmatory study (NCT07191912) was later withdrawn, so the situation is still developing — but for people with the SORD subtype specifically, this is real, targeted progress. A separate study is also looking at a related drug, epalrestat, in SORD-CMT (NCT05777226).

Gene-targeted and other approaches — earlier but promising

Because CMT1A is fundamentally a "too much PMP22" problem, several groups are developing therapies designed to turn down the overactive PMP22 gene (using approaches such as antisense oligonucleotides and gene therapy). These are in early development. A gene therapy delivering a nerve-supporting protein (neurotrophin-3) has also been studied for CMT1A (NCT03520751). None of these is available outside research yet, but they target the root cause and represent the field's most hopeful long-term direction. Meanwhile, large research registries and natural-history studies — such as the Inherited Neuropathies Consortium (NCT01193088) and a biomarker study in early CMT1A (NCT07049588) — are quietly essential, because they build the tools and the patient networks that future treatment trials depend on.

How we got here — the research story in plain language

Understanding a little of the history helps you judge the news you will hear about CMT. The condition was first described in 1886 by three doctors — Charcot and Marie in France and Tooth in England — whose names it still carries. The modern turning point came in 1991, when researchers (Lupski et al., 1991) discovered that the most common form, CMT1A, is caused by a duplication of the PMP22 gene — the finding that made genetic testing possible and defined the target that today's drug programs aim at. Since then, the pieces have accumulated steadily: the GJB1 gene behind the X-linked form (CMTX1) was identified in 1993, and MFN2 (the main cause of the axonal type CMT2A) in 2004. A pivotal negative result came from the large ascorbic-acid (vitamin C) trials, reported by Pareyson et al. in Lancet Neurology in 2011 (the CMT-TRIAAL and CMT-TRAUK studies), which showed vitamin C did not help CMT1A — an important lesson that supplements marketed for CMT rarely survive proper testing. More recently, a genuinely new and potentially treatable subtype, CMT-SORD, was defined by Cortese et al. in Nature Genetics in 2020. The PXT3003 program then reported its main phase 3 results (Attarian et al., 2021, for the earlier PLEO-CMT study), and its confirmatory PREMIER trial reported in 2024 that it missed its primary goal. The through-line is encouraging but sobering: real scientific progress, several honest disappointments, and a field that now has the tools (genetic diagnosis, validated rating scales, registries) to test treatments properly. Ask your neurologist: "Where does the current research actually stand for my type of CMT, and is any of it close enough to matter for me?"

How the pieces work together (why the combination matters)

One reason supportive care works so well is that the parts reinforce each other — there is a genuine stacking, or synergy, when they are used together rather than one at a time. A well-fitted ankle-foot brace reduces tripping, which lets you stay active; staying active through physical therapy maintains the strength and balance that make the brace even more effective; good footwear and foot care prevent the wounds and pain that would otherwise cut activity short; and treating pain keeps you moving, which protects mobility and mood. Layered on top, the one habit that protects all of this is nerve protection — avoiding the vincristine-type drugs that could undo years of careful management in a single course. No single measure is a cure, but the combined effect of braces plus therapy plus foot care plus pain control plus nerve protection is what keeps most people with CMT mobile and independent for the long term. Ask your therapist: "Can we build one plan that ties my braces, exercises, and foot care together, rather than treating each on its own?"

Questions to ask your doctor

• What can we do to keep me mobile and independent over the long term?
• If I'm planning a pregnancy, how should we prepare?
• Are there clinical trials relevant to my type of CMT, and should I join a registry?

Support & Resources

Below are guidance on living well, support organizations, a glossary, what does not work, and the sources behind this guide.

Living well with CMT

Beyond medical care, several things help daily life. Stay active and engaged — appropriate exercise and therapy maintain function and mood. Invest in the right footwear and braces, which make a bigger difference to walking and confidence than people often expect, and look after your feet with regular checks. Build a care team familiar with CMT, and keep a simple record of your diagnosis and the medicines you must avoid to share with any new clinician. Address the emotional side: living with a progressive condition can be stressful, and counseling and peer support genuinely help. And connect with the CMT community — organizations offer education, practical tips, and a sense of not being alone, which many people find invaluable.

Practical day-to-day strategies

Small, consistent habits make a real difference with CMT. For walking and balance, use your braces and well-fitting, supportive footwear consistently — they prevent trips and conserve energy — and keep up the therapy exercises that maintain strength and stability. For your feet, check them daily for any redness, blisters, or sores (because reduced sensation means you might not feel an injury), keep nails and skin cared for, and treat any wound promptly. For hands and fine tasks, occupational therapy can suggest tools and techniques (built-up grips, button hooks, voice typing) that preserve independence. For energy, pace demanding activities and build in rest; fatigue is a real part of CMT, not laziness. For safety at home, good lighting, clear floors, grab bars, and handrails reduce falls. And carry a simple medical summary — your diagnosis and the medicines you must avoid (especially vincristine) — so any clinician, including in an emergency, knows to protect your nerves. None of these are complicated, but together they keep you mobile, safe, and independent.

For family and caregivers

Family and caregivers can help in valuable ways. Understand that CMT's fatigue and the effort of walking are real and often invisible — planning around energy levels, rather than pushing through, helps everyone. Help keep the practical supports in place: attending appointments, keeping braces and footwear in good repair, and watching for foot injuries the person may not feel. Be a second set of eyes for the medication safety point — making sure every new doctor, dentist, or hospital knows about the CMT diagnosis and the need to avoid nerve-toxic drugs. Support independence rather than taking over: the goal is to enable the person to do as much as they safely can. And because CMT is inherited, relatives may have their own questions about testing and risk, which genetic counseling can address for the whole family. Caregivers should also look after themselves and tap into the CMT community for shared experience and practical tips.

Why joining a registry or community helps

One simple, low-effort step that can make a real difference is connecting with a patient registry and the CMT community. A registry is a secure database of people with CMT who agree to share some health information for research; joining can connect you to clinical trials you might be eligible for (researchers use registries to find participants — important now that the first disease-targeted treatments are being tested), and it ensures your experience contributes to understanding the condition and speeding new treatments. Beyond research, organizations like the CMTA and Hereditary Neuropathy Foundation offer something just as valuable: practical, lived-experience knowledge — tips on braces and footwear, navigating work and benefits, the all-important list of medicines to avoid, and the reassurance of connecting with others who understand. For a relatively common but still under-recognized condition, this kind of organized community has helped drive research investment and is part of why the treatment pipeline has grown. Even if you're not currently interested in a trial, being connected keeps the door open and strengthens the collective effort — and many people find the community itself makes living with CMT noticeably easier.

Mountain West / Utah

• University of Utah Health — Neuromuscular/Neurology program (Salt Lake City), with EMG/nerve-conduction testing, genetics, physical/occupational therapy, and orthotics; appointments via University of Utah Health (801-585-7575).
• Intermountain Health — neurology, rehabilitation, and orthotics services across the region.
• Shriners Children's (Salt Lake City) — orthopedic and orthotic care for children with CMT (including foot/limb issues).
• George E. Wahlen VA Medical Center (Salt Lake City) — neurology and rehabilitation for eligible veterans.

National organizations

• Charcot-Marie-Tooth Association (CMTA) (cmtausa.org) — the leading CMT organization: education, a Centers of Excellence network, a list of medicines to avoid/use with caution, support, and research/trial information.
• Hereditary Neuropathy Foundation (HNF) (hnf-cure.org) — patient support, education, and research.
• Muscular Dystrophy Association (MDA) (mda.org; 1-833-275-6321) — care centers and resources for neuromuscular conditions including CMT.
• NINDS (ninds.nih.gov) and ClinicalTrials.gov — for research and trial information.

What CMT care costs — a practical money guide

Because there is no expensive disease-modifying drug for CMT, most costs are for devices, therapy, testing, and (sometimes) surgery — and the good news is that these are usually covered, at least in part, by Medicare and most private insurance when documented as medically necessary. The figures below are rough US estimates for 2026, meant to help you plan and ask the right questions; actual amounts vary widely by region, supplier, and plan, so treat them as ballparks and confirm with your own insurer. Where a number would be a guess, it is flagged as an estimate rather than omitted.

Genetic testing and counseling

• CMT gene panel (next-generation sequencing): commercial list prices commonly run about $300 to $1,500, but many families pay far less — several labs and CMT organizations run sponsored/no-charge testing programs for people with a clinical diagnosis, so ask before assuming a cost.
• PMP22 duplication/deletion (MLPA) as a single test: roughly $200 to $500 (estimate); often the first and only test needed to confirm CMT1A.
• Broader whole-exome sequencing (if panels are negative): roughly $1,000 to $2,000 (estimate), increasingly covered when it will change management.
• Genetic counseling visit: about $150 to $300 out of pocket if not covered; frequently billed as a specialty visit and covered. Cascade (family) testing for a known variant is often cheaper and sometimes free.

Ask your genetics team: "Is there a sponsored or no-cost testing program I qualify for, and if my insurance denies the panel, will you help me appeal?"

Braces, orthotics, and footwear

• Off-the-shelf (prefabricated) AFO: about $100 to $500 (estimate).
• Custom-molded AFO: commonly $1,000 to $3,000 in the private market; under Medicare, the 2026 allowed amount is roughly $637 to $849 for a molded solid-ankle device and $818 to $1,090 for one with an ankle joint, with Medicare Part B paying 80% after the annual deductible ($283 in 2026), leaving about 20% coinsurance.
• Carbon-fiber dynamic AFO (lightweight, spring-like): often $1,500 to $3,000+ (estimate); many people find these transform walking, so they can be worth an appeal if initially denied.
• Custom foot orthotics/insoles for high arches: about $200 to $600 (estimate); therapeutic or orthopedic shoes about $100 to $300 a pair (estimate).

Ask your orthotist: "What will my share of this brace be after insurance, and would a lighter carbon-fiber AFO be worth trying if we document the need?"

Therapy, mobility aids, and home safety

• Physical or occupational therapy: roughly $75 to $350 per visit if paying out of pocket; with insurance you usually pay a copay of about $20 to $75. Medicare no longer caps medically necessary therapy, and "maintenance therapy" is allowed under the Jimmo standard — good to know if a plan pushes back on ongoing sessions.
• Simple aids: a cane about $15 to $40; walking poles about $30 to $100; forearm crutches about $40 to $100; a rollator/walker about $70 to $300 (estimates).
• Wheelchairs and scooters (often used selectively for distance): a basic manual wheelchair from about $100 to well over $1,000; a mobility scooter roughly $800 to $4,000+ (estimates); these may be covered as durable medical equipment when medically justified.
• Home safety: grab bars about $20 to $60 each plus installation; a ramp from about $100 (portable) to $3,000+ (installed).
• A CMT safety measure worth a few dollars: a medical-alert bracelet about $15 to $50, or a MedicAlert-type membership around $40 a year — cheap insurance against a dangerous drug being given in an emergency.

Foot/ankle surgery and disability support

When foot deformity needs surgery (tendon transfers, osteotomies, sometimes fusion), the total charges are highly variable but often run into the tens of thousands of dollars (a rough range of $10,000 to $40,000+ depending on the procedure and setting), the large majority of which is covered when the surgery is medically necessary — so the practical question is your out-of-pocket maximum, not the sticker price. People with significant functional limitation may also qualify for Social Security disability (SSDI or SSI). Ask your surgeon's office: "Can you give me an estimate of my out-of-pocket cost after insurance, and confirm this is billed as medically necessary?" The CMTA and Hereditary Neuropathy Foundation can help with insurance navigation and appeals.

Getting good care wherever you are

CMT care is mostly about access to the right supportive services rather than a single specialist, and there are ways to get good care wherever you live. A neuromuscular clinic or CMTA Center of Excellence can confirm the diagnosis and type and set up a clear plan, which local clinicians and therapists then help deliver; telehealth is increasingly available for follow-up. The most valuable services to access are physical and occupational therapy and a good orthotist for braces — these do the heavy lifting in maintaining function. Crucially, the one thing every clinician you see must know — even those far from CMT expertise — is that you have CMT and that nerve-toxic medicines must be avoided; keep this on a card and in your records. National organizations like the CMTA and Hereditary Neuropathy Foundation can help you find experienced clinicians, navigate insurance and access to braces and devices, and connect with the CMT community and trials. Because research interest in CMT is growing, awareness and access to knowledgeable care are gradually improving.

International access

CMT is recognized worldwide, and the foundation of care — diagnosis, therapy, braces and orthotics, foot care, and avoidance of nerve-toxic medicines — is achievable wherever neurology and rehabilitation services exist; the supportive, multidisciplinary model is broadly similar across countries. Access to genetic testing, specialized neuromuscular clinics, and advanced orthotics varies by region. The investigational CMT1A treatment PXT3003 did not meet the primary goal of its confirmatory PREMIER trial (reported in 2024) and is not approved; no CMT drug is yet broadly approved. The universal priorities are the same everywhere: confirm the diagnosis (and ideally the type), maintain function with therapy and orthoses, protect the feet, and — critically — ensure every clinician knows to avoid vincristine and other nerve-toxic drugs.

The emotional side

CMT is not only physical — living with a slowly progressive, visible condition can carry a real emotional weight that deserves acknowledgment. It is common to feel frustration at changing abilities, worry about the future, self-consciousness about braces or an altered gait, or sadness about activities that have become harder. These feelings are normal and are not a sign of weakness or of “not coping.” Several things help: connecting with others who have CMT (through the CMTA, Hereditary Neuropathy Foundation, or online communities) so you don't feel alone; counseling or therapy if low mood or anxiety becomes persistent; focusing on what you can do and adapting how you do other things rather than giving them up; and being open with family and friends about what helps. Many people find that the practical steps in this guide — getting the right braces, staying active, protecting their nerves — also restore a sense of control that improves mood. If the emotional side becomes hard, tell your care team; psychological support is a legitimate and valuable part of CMT care, not separate from it.

What does not work

Being clear about limits helps. There is currently no medicine approved to cure or slow CMT (the most-studied candidate, PXT3003 for CMT1A, missed the primary goal of its confirmatory PREMIER trial in 2024 and remains investigational). Earlier trials of high-dose vitamin C for CMT1A, once hoped to help, did not show benefit in large studies and are not recommended. No supplement or alternative therapy has been shown to treat CMT, and some (including high-dose vitamin B6) can themselves harm nerves, so tell your team about anything you take. And it bears repeating that certain prescription medicines — above all vincristine — can seriously worsen CMT and must be avoided. The genuinely effective “treatments” today are the supportive ones: therapy, braces, foot care, exercise, and pain management.

A hopeful, realistic close

Living with CMT means holding two truths together. It is a lifelong, slowly progressive condition with no cure yet — that is real. But it is also a condition where most people stay active and independent, where the supportive treatments (braces, therapy, foot care, exercise, pain management) genuinely preserve function and quality of life, and where, for the first time, a disease-targeted treatment is in late-stage trials. The people who do best are those who stay engaged: using the right braces and footwear, keeping up with therapy and sensible exercise, looking after their feet, protecting their nerves by avoiding harmful medicines, planning ahead for family questions, and staying connected to knowledgeable care and a supportive community. CMT may change how you do some things, but it rarely needs to stop you from living a full, meaningful life. Use this guide as a practical companion, lean on your care team and on organizations like the CMTA and Hereditary Neuropathy Foundation, and take encouragement from a research field that is, after many years, finally moving toward treatments aimed at the disease itself.

Key sources

This guide is based on standard neurology and neuromuscular references on CMT classification (CMT1/CMT2/CMTX and the PMP22, MPZ, MFN2, and GJB1 genes), diagnosis (nerve conduction studies and genetic testing), and supportive management (therapy, orthoses, foot care, pain, and avoidance of neurotoxic drugs such as vincristine); the Charcot-Marie-Tooth Association guidance on medicines to avoid; and the CMT1A treatment trials of PXT3003, plus ClinicalTrials.gov registry data current as of July 2026. Selected sources:

• Lupski JR, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell, 1991 — the discovery of the PMP22 duplication.
• Bergoffen J, et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science, 1993 — the GJB1 gene behind CMTX1.
• Zuchner S, et al. Mutations in the mitochondrial GTPase mitofusin 2 (MFN2) cause CMT type 2A. Nature Genetics, 2004.
• Pareyson D, et al. Ascorbic acid in CMT1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurology, 2011 — the trial showing vitamin C did not help.
• Attarian S, et al. A double-blind, placebo-controlled, randomized trial of PXT3003 for CMT1A. Orphanet Journal of Rare Diseases, 2021 (PMID 34656144).
• Cortese A, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy. Nature Genetics, 2020 — defining the CMT-SORD subtype.
• PREMIER phase 3 trial of PXT3003 in CMT1A (NCT04762758) — reported in 2024 as not meeting its primary endpoint.
• INSPIRE trial of govorestat in CMT-SORD (NCT05397665) — results reported through 2025; the drug is investigational and not approved.
• Charcot-Marie-Tooth Association (cmtausa.org) — medication-safety guidance (vincristine and other neurotoxic drugs) and Centers of Excellence.
• Professional guideline and consensus references from neuromuscular medicine on CMT diagnosis and supportive care; US FDA prescribing information (DailyMed) for the symptom medicines named above.

Trial identifiers and statuses were checked against ClinicalTrials.gov as of July 2026. This guide is educational and is not a substitute for advice from your own medical team.